Affordable Access

deepdyve-link
Publisher Website

Screening and pharmacodynamic evaluation of the anti-respiratory syncytial virus activity of butene lactones in vitro and in vivo.

Authors
  • Wang, Zhenya1, 2
  • Tan, Yayun1, 2
  • Mou, Xiaodong1
  • Wang, Congcong1, 2
  • Li, Yuanyuan1
  • Xiao, Fan1, 2
  • Hu, Xiaoning1, 2
  • Liu, Hongmin1, 2
  • Xu, Haiwei1, 2
  • 1 Collaborative Innovation Center of New Drug Research and Safety Evaluation, Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, Zhengzhou University, Zhengzhou, Henan, China. , (China)
  • 2 Key Laboratory of "Runliang" Antiviral Medicines Research and Development, Institute of Drug Discovery and Development, Zhengzhou University, Zhengzhou, China. , (China)
Type
Published Article
Journal
Journal of Medical Virology
Publisher
Wiley (John Wiley & Sons)
Publication Date
Jan 01, 2020
Volume
92
Issue
1
Pages
17–25
Identifiers
DOI: 10.1002/jmv.25586
PMID: 31475735
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

A series of butene lactones were synthesized and these compounds were tested for anti-respiratory syncytial virus (RSV) activity in vitro. Three compounds exhibited an antiviral effect, the highest of which was compound 6b3 with an effective concentration 50% of 6.35 μM. The effects of 6b3 were then evaluated in vivo and a significant reduction in the lung index caused by RSV was detected. Reduced inflammatory infiltration and necrosis of the lungs were revealed by histopathology and gross pathology. Activation of an early immune response by 6b3 was also observed by cytokine analysis via a real-time polymerase chain reaction. These results indicated that 6b3 has an anti-RSV effect both in vitro and in vivo, and is a possible candidate compound for the development of an anti-RSV drug in the future. © 2019 Wiley Periodicals, Inc.

Report this publication

Statistics

Seen <100 times